Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
←Back to story

Pfizer gets into in vivo CAR-T through licensing deal with Chinese biotech

EndpointsView source article

Part of story

Pfizer licenses CAR-T therapies from China's Starna in up to $2.6B deal

Pfizer struck an exclusive licensing agreement with Starna Therapeutics to develop three in vivo CAR-T therapies for autoimmune diseases, in a deal worth up to $2.6 billion.

Nov 18, 2026·2 sourcesCAR T-cell therapyAutoimmune disease treatmentsCorporate strategyPharmaceutical IndustryDrug developmentImmunotherapyBiotechnology
Pfizer licenses CAR-T therapies from China's Starna in up to $2.6B deal
00

Other sources for this story

Reuters

Pfizer licenses CAR-T therapies from China's Starna in up to $2.6 billion deal | Reuters